{"altmetric_id":1341110,"counts":{"readers":{"mendeley":14,"citeulike":0,"connotea":0},"googleplus":{"unique_users_count":1,"unique_users":["Juan Carlos Ivancevich"],"posts_count":2},"total":{"posts_count":22},"twitter":{"unique_users_count":11,"unique_users":["FUNDACIONLIBRA","alsaeedi68","asthma_papers","SocLatAlergia","vivirsinalergia","ERSpublications","Interasma","Aller_MD","PedRheum","SVAAI","drarequena"],"posts_count":20}},"selected_quotes":["ERJ ed's choice: Omalizumab improves asthma cont'l in children w\/ severe allergic asthma, is generally well tolerated"],"citation":{"abstract":"Omalizumab has been shown to reduce exacerbation rates in moderate to severe allergic asthma. Our aim was to evaluate omalizumab efficacy and safety in a real-life setting in severe asthmatic children. 104 children (aged 6-18 years), followed up in paediatric pulmonary tertiary care centres, were included at the beginning of omalizumab treatment. Asthma control levels, exacerbations, inhaled corticosteroid dose, lung function and adverse events were evaluated over 1 year. Children were characterised by allergic sensitisation to three or more allergens (66%), high IgE levels (mean 1125 kU \u00b7 L(-1)), high rate of exacerbations (4.4 per year) and healthcare use during the previous year, and high inhaled corticosteroid dose (mean 703 \u03bcg equivalent fluticasone per day). Asthma control levels defined as good, partial or poor, improved from 0%, 18% and 82% at entry to 53%, 30% and 17% at week 20, and to 67%, 25% and 8% at week 52, respectively (p<0.0001). Exacerbation and hospitalisation rates dropped by 72% and 88.5%, respectively. At 12 months, forced expiratory volume in 1 s improved by 4.9% (p=0.023), and inhaled corticosteroid dose decreased by 30% (p<0.001). Six patients stopped omalizumab for related significant adverse events. Omalizumab improved asthma control in children with severe allergic asthma and was generally well tolerated. The observed benefit was greater than that reported in clinical trials.","abstract_source":"pubmed","altmetric_jid":"4f6fa6173cf058f610007384","authors":["Antoine Deschildre","Christophe Marguet","Julia Salleron","Isabelle Pin","Jean-Luc Ritti\u00e9","Jocelyne Derelle","Rola Abou Taam","Mickael Fayon","Jacques Brouard","Jean Christophe Dubus","Daniel Siret","Guillaume Pouessel","Laurent Beghin","Jocelyne Just"],"doi":"10.1183\/09031936.00149812","first_seen_on":"2013-04-05T13:47:11+00:00","issns":["1399-3003"],"journal":"European Respiratory Journal","last_mentioned_on":1403778412,"links":["http:\/\/erj.ersjournals.com\/content\/early\/2013\/03\/20\/09031936.00149812.short?rss=1","http:\/\/m.erj.ersjournals.com\/content\/42\/5\/1224","http:\/\/m.erj.ersjournals.com\/content\/42\/5\/1224.short?rss=1&utm_content=bufferdeae0&utm_source=buffer&utm_medium=twitter&utm_campaign=Buffer","http:\/\/erj.ersjournals.com\/content\/42\/5\/1224.full?ijkey=t1lxYF4ES3yoA&keytype=ref&siteid=ersjnls%3fctkey=twitter","http:\/\/erj.ersjournals.com\/content\/early\/2013\/03\/20\/09031936.00149812.abstract","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23520319?dopt=Abstract&utm_source=dlvr.it&utm_medium=twitter"],"pdf_url":"http:\/\/erj.ersjournals.com\/content\/early\/2013\/03\/20\/09031936.00149812.full.pdf","pmid":"23520319","pubdate":"2013-01-01T00:00:00+00:00","publisher_subjects":[{"name":"Medical And Health Sciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"subjects":["pulmonarymedicine"],"title":"Add-on omalizumab in children with severe allergic asthma: a one year real life survey.","type":"article","mendeley_url":"http:\/\/www.mendeley.com\/research\/addon-omalizumab-children-severe-allergic-asthma-1year-real-life-survey-8"},"altmetric_score":{"score":5.35,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":5.35},"context_for_score":{"all":{"total_number_of_other_articles":8444188,"mean":7.0997070730352,"rank":1572458,"this_scored_higher_than_pct":81,"this_scored_higher_than":6865618,"rank_type":"exact","sample_size":8444188,"percentile":81},"similar_age_3m":{"total_number_of_other_articles":120626,"mean":6.8511645844561,"rank":22693,"this_scored_higher_than_pct":81,"this_scored_higher_than":97812,"rank_type":"exact","sample_size":120626,"percentile":81},"this_journal":{"total_number_of_other_articles":3886,"mean":6.9436900900901,"rank":1083,"this_scored_higher_than_pct":71,"this_scored_higher_than":2797,"rank_type":"exact","sample_size":3886,"percentile":71},"similar_age_this_journal_3m":{"total_number_of_other_articles":30,"mean":8.5336551724138,"rank":9,"this_scored_higher_than_pct":70,"this_scored_higher_than":21,"rank_type":"exact","sample_size":30,"percentile":70}}},"demographics":{"poster_types":{"member_of_the_public":9,"researcher":1,"science_communicator":1},"users":{"twitter":{"cohorts":{"Members of the public":9,"Science communicators (journalists, bloggers, editors)":1,"Scientists":1}},"mendeley":{"by_status":{"Unspecified":1,"Professor > Associate Professor":1,"Researcher":2,"Student  > Ph. D. Student":2,"Student  > Postgraduate":1,"Other":2,"Student  > Master":2,"Student  > Bachelor":2,"Lecturer > Senior Lecturer":1},"by_discipline":{"Medicine and Dentistry":7,"Immunology and Microbiology":1,"Economics, Econometrics and Finance":2,"Agricultural and Biological Sciences":2,"Unspecified":1,"Pharmacology, Toxicology and Pharmaceutical Science":1}}},"geo":{"twitter":{"KW":1,"MX":1,"AR":1,"SE":1,"VE":1,"ES":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/#!\/FUNDACIONLIBRA\/status\/329609061131751424","license":"public","rt":["Aller_MD"],"citation_ids":[1341110],"posted_on":"2013-05-01T14:51:38+00:00","author":{"name":"Fundaci\u00f3n Libra","url":"http:\/\/www.fundacionlibra.org","image":"https:\/\/pbs.twimg.com\/profile_images\/1130674087\/logo_normal.jpg","description":"Fundaci\u00f3n LIBRA (Fundaci\u00f3n Lucha Integral contra la Broncopat\u00eda, la Rinitis y el Asma)","id_on_source":"FUNDACIONLIBRA","tweeter_id":"194818089","geo":{"lt":null,"ln":null},"followers":362},"tweet_id":"329609061131751424"},{"url":"https:\/\/twitter.com\/alsaeedi68\/status\/396109588019556352","license":"public","citation_ids":[1341110],"posted_on":"2013-11-01T03:00:59+00:00","author":{"name":"Dr.Abdullah Alsaeedi","image":"https:\/\/pbs.twimg.com\/profile_images\/2841456131\/87a852440416c52ebde11967e19ae55b_normal.jpeg","description":"Pulmonary&Sleep Medicine Consultant \u0625\u0633\u062a\u0634\u0627\u0631\u064a \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u062c\u0647\u0627\u0632 \u0627\u0644\u062a\u0646\u0641\u0633\u064a \u0648\u0637\u0628 \u0627\u0644\u0646\u0648\u0645.\n\u0627\u0644\u0632\u0645\u0627\u0644\u0629 \u0627\u0644\u0643\u0646\u062f\u064a\u0629 \u0648\u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0644\u0644\u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0628\u0627\u0637\u0646\u064a\u0629 \u0648\u0627\u0644\u062c\u0647\u0627\u0632 \u0627\u0644\u062a\u0646\u0641\u0633\u064a","id_on_source":"alsaeedi68","tweeter_id":"921416389","geo":{"lt":29.5,"ln":47.75,"country":"KW"},"followers":1599},"tweet_id":"396109588019556352"},{"url":"https:\/\/twitter.com\/asthma_papers\/status\/482107720892309504","license":"datasift","citation_ids":[1341110],"posted_on":"2014-06-26T10:26:52+00:00","author":{"name":"Asthma Papers","url":"https:\/\/github.com\/roblanf\/phypapers","image":"https:\/\/pbs.twimg.com\/profile_images\/439482171208646656\/OWe4b0kE_normal.jpeg","description":"RSS feed for #asthma papers in #Pubmed. Create a feed of your own using instructions here:","id_on_source":"asthma_papers","tweeter_id":"2366030767","geo":{"lt":null,"ln":null},"followers":566},"tweet_id":"482107720892309504"},{"url":"https:\/\/twitter.com\/SocLatAlergia\/status\/396237909244010496","license":"public","rt":["Aller_MD"],"citation_ids":[1341110],"posted_on":"2013-11-01T11:30:53+00:00","author":{"name":"SLaai","url":"http:\/\/www.slaai.org","image":"https:\/\/pbs.twimg.com\/profile_images\/469173940116393986\/4DtHZNic_normal.png","description":"Sociedad Latinoamericana de Alergia, Asma e Inmunolog\u00eda","id_on_source":"SocLatAlergia","tweeter_id":"367878837","geo":{"lt":null,"ln":null},"followers":1254},"tweet_id":"396237909244010496"},{"url":"https:\/\/twitter.com\/FUNDACIONLIBRA\/status\/396237393843736576","license":"public","rt":["Aller_MD"],"citation_ids":[1341110],"posted_on":"2013-11-01T11:28:51+00:00","author":{"name":"Fundaci\u00f3n Libra","url":"http:\/\/www.fundacionlibra.org","image":"https:\/\/pbs.twimg.com\/profile_images\/1130674087\/logo_normal.jpg","description":"Fundaci\u00f3n LIBRA (Fundaci\u00f3n Lucha Integral contra la Broncopat\u00eda, la Rinitis y el Asma)","id_on_source":"FUNDACIONLIBRA","tweeter_id":"194818089","geo":{"lt":null,"ln":null},"followers":362},"tweet_id":"396237393843736576"},{"url":"https:\/\/twitter.com\/vivirsinalergia\/status\/316198299470270464","license":"public","rt":["Aller_MD"],"citation_ids":[1341110],"posted_on":"2013-03-25T14:42:03+00:00","author":{"name":"Alberto Monteverde","url":"http:\/\/vivirsinalergia.com","image":"https:\/\/pbs.twimg.com\/profile_images\/909056900720869376\/bRqMvT42_normal.jpg","description":"Dr. Alberto Monteverde Maldonado MD. Alergia e Inmunolog\u00eca Cl\u00ecnica. Medicina Interna. M.A.C.P. C\u00e1tedra de Inmunolog\u00eda B\u00e1sica UDS. Clinica del Noroeste. ISSSTE.","id_on_source":"vivirsinalergia","tweeter_id":"177699764","geo":{"lt":29.0971,"ln":-110.95749,"country":"MX"},"followers":3325},"tweet_id":"316198299470270464"},{"url":"https:\/\/twitter.com\/ERSpublications\/status\/397242459493007360","license":"public","citation_ids":[1341110],"posted_on":"2013-11-04T06:02:37+00:00","author":{"name":"ERS publications","url":"http:\/\/www.ersbookshop.com","image":"https:\/\/pbs.twimg.com\/profile_images\/725961348232912897\/jBGSJH5b_normal.jpg","description":"European Respiratory Journal, European Respiratory Review, ERJ Open Research, Breathe, the ERS Monograph and ERS Handbooks, and European Lung White Book","id_on_source":"ERSpublications","tweeter_id":"424241621","geo":{"lt":null,"ln":null},"followers":6146},"tweet_id":"397242459493007360"},{"url":"http:\/\/twitter.com\/#!\/FUNDACIONLIBRA\/status\/329196617347506176","license":"public","citation_ids":[1341110],"posted_on":"2013-04-30T11:32:44+00:00","author":{"name":"Fundaci\u00f3n Libra","url":"http:\/\/www.fundacionlibra.org","image":"https:\/\/pbs.twimg.com\/profile_images\/1130674087\/logo_normal.jpg","description":"Fundaci\u00f3n LIBRA (Fundaci\u00f3n Lucha Integral contra la Broncopat\u00eda, la Rinitis y el Asma)","id_on_source":"FUNDACIONLIBRA","tweeter_id":"194818089","geo":{"lt":null,"ln":null},"followers":362},"tweet_id":"329196617347506176"},{"url":"http:\/\/twitter.com\/#!\/Interasma\/status\/329196617209098240","license":"public","citation_ids":[1341110],"posted_on":"2013-04-30T11:32:44+00:00","author":{"name":"Interasma","url":"http:\/\/www.interasma.org","image":"https:\/\/pbs.twimg.com\/profile_images\/481070665450016770\/o6EbOA8x_normal.jpeg","description":"Interasma is an international health organization focused on all aspects of asthma which bridges the gap between academia and the world of clinical practice.","id_on_source":"Interasma","tweeter_id":"147594153","geo":{"lt":null,"ln":null},"followers":1584},"tweet_id":"329196617209098240"},{"url":"http:\/\/twitter.com\/#!\/SocLatAlergia\/status\/329196617095852032","license":"public","citation_ids":[1341110],"posted_on":"2013-04-30T11:32:44+00:00","author":{"name":"SLaai","url":"http:\/\/www.slaai.org","image":"https:\/\/pbs.twimg.com\/profile_images\/469173940116393986\/4DtHZNic_normal.png","description":"Sociedad Latinoamericana de Alergia, Asma e Inmunolog\u00eda","id_on_source":"SocLatAlergia","tweeter_id":"367878837","geo":{"lt":null,"ln":null},"followers":1254},"tweet_id":"329196617095852032"},{"url":"http:\/\/twitter.com\/#!\/Aller_MD\/status\/329196616873549824","license":"public","citation_ids":[1341110],"posted_on":"2013-04-30T11:32:44+00:00","author":{"name":"Juan C Ivancevich MD","url":"http:\/\/www.ivancevichmd.blogspot.com","image":"https:\/\/pbs.twimg.com\/profile_images\/906525202787520514\/NdEfNrQI_normal.jpg","description":"Allergist - Twittering on #allergy, #asthma & #immunology. Associate Professor of Immunology, del Salvador University, WAO website Chief Editor","id_on_source":"Aller_MD","tweeter_id":"23184067","geo":{"lt":-34.61315,"ln":-58.37723,"country":"AR"},"followers":5437},"tweet_id":"329196616873549824"},{"url":"http:\/\/twitter.com\/#!\/PedRheum\/status\/329197391758626817","license":"public","rt":["Aller_MD"],"citation_ids":[1341110],"posted_on":"2013-04-30T11:35:49+00:00","author":{"name":"PedRheum","image":"https:\/\/pbs.twimg.com\/profile_images\/1573052164\/image_normal.jpg","description":"Pediatrics, Rheumatology and Pediatric Rheumatology","id_on_source":"PedRheum","tweeter_id":"384978060","geo":{"lt":59.36661,"ln":16.5077,"country":"SE"},"followers":989},"tweet_id":"329197391758626817"},{"url":"http:\/\/twitter.com\/#!\/SVAAI\/status\/329302302420766721","license":"public","rt":["Aller_MD"],"citation_ids":[1341110],"posted_on":"2013-04-30T18:32:41+00:00","author":{"name":"SVAAI","url":"http:\/\/www.svaai.org.ve","image":"https:\/\/pbs.twimg.com\/profile_images\/470252915127758849\/US_upRiT_normal.jpeg","description":"Fundada en 1956, la Sociedad Venezolana de Alergia, Asma e Inmunolog\u00eda agrupa profesionales para la promoci\u00f3n y el desarrollo de la especialidad en Venezuela","id_on_source":"SVAAI","tweeter_id":"264420077","geo":{"lt":10.48801,"ln":-66.87919,"country":"VE"},"followers":281},"tweet_id":"329302302420766721"},{"url":"https:\/\/twitter.com\/FUNDACIONLIBRA\/status\/316166957130981376","license":"public","citation_ids":[1341110],"posted_on":"2013-03-25T12:37:31+00:00","author":{"name":"Fundaci\u00f3n Libra","url":"http:\/\/www.fundacionlibra.org","image":"https:\/\/pbs.twimg.com\/profile_images\/1130674087\/logo_normal.jpg","description":"Fundaci\u00f3n LIBRA (Fundaci\u00f3n Lucha Integral contra la Broncopat\u00eda, la Rinitis y el Asma)","id_on_source":"FUNDACIONLIBRA","tweeter_id":"194818089","geo":{"lt":null,"ln":null},"followers":362},"tweet_id":"316166957130981376"},{"url":"https:\/\/twitter.com\/Aller_MD\/status\/316166956585738240","license":"public","citation_ids":[1341110],"posted_on":"2013-03-25T12:37:31+00:00","author":{"name":"Juan C Ivancevich MD","url":"http:\/\/www.ivancevichmd.blogspot.com","image":"https:\/\/pbs.twimg.com\/profile_images\/906525202787520514\/NdEfNrQI_normal.jpg","description":"Allergist - Twittering on #allergy, #asthma & #immunology. Associate Professor of Immunology, del Salvador University, WAO website Chief Editor","id_on_source":"Aller_MD","tweeter_id":"23184067","geo":{"lt":-34.61315,"ln":-58.37723,"country":"AR"},"followers":5437},"tweet_id":"316166956585738240"},{"url":"https:\/\/twitter.com\/Interasma\/status\/316166957223247874","license":"public","citation_ids":[1341110],"posted_on":"2013-03-25T12:37:31+00:00","author":{"name":"Interasma","url":"http:\/\/www.interasma.org","image":"https:\/\/pbs.twimg.com\/profile_images\/481070665450016770\/o6EbOA8x_normal.jpeg","description":"Interasma is an international health organization focused on all aspects of asthma which bridges the gap between academia and the world of clinical practice.","id_on_source":"Interasma","tweeter_id":"147594153","geo":{"lt":null,"ln":null},"followers":1584},"tweet_id":"316166957223247874"},{"url":"https:\/\/twitter.com\/SocLatAlergia\/status\/316166956887732224","license":"public","citation_ids":[1341110],"posted_on":"2013-03-25T12:37:31+00:00","author":{"name":"SLaai","url":"http:\/\/www.slaai.org","image":"https:\/\/pbs.twimg.com\/profile_images\/469173940116393986\/4DtHZNic_normal.png","description":"Sociedad Latinoamericana de Alergia, Asma e Inmunolog\u00eda","id_on_source":"SocLatAlergia","tweeter_id":"367878837","geo":{"lt":null,"ln":null},"followers":1254},"tweet_id":"316166956887732224"},{"url":"https:\/\/twitter.com\/Aller_MD\/status\/396170063193313281","license":"public","citation_ids":[1341110],"posted_on":"2013-11-01T07:01:18+00:00","author":{"name":"Juan C Ivancevich MD","url":"http:\/\/www.ivancevichmd.blogspot.com","image":"https:\/\/pbs.twimg.com\/profile_images\/906525202787520514\/NdEfNrQI_normal.jpg","description":"Allergist - Twittering on #allergy, #asthma & #immunology. Associate Professor of Immunology, del Salvador University, WAO website Chief Editor","id_on_source":"Aller_MD","tweeter_id":"23184067","geo":{"lt":-34.61315,"ln":-58.37723,"country":"AR"},"followers":5437},"tweet_id":"396170063193313281"},{"url":"https:\/\/twitter.com\/drarequena\/status\/396216192668798976","license":"public","rt":["Aller_MD"],"citation_ids":[1341110],"posted_on":"2013-11-01T10:04:36+00:00","author":{"name":"GloriaRequena","url":"http:\/\/www.facebook.com\/#!\/pages\/Consulta-Alergia-Dra-Requena\/173336776050017","image":"https:\/\/pbs.twimg.com\/profile_images\/2218872926\/17032012436_normal.jpg","description":"Alerg\u00f3loga, Farmac\u00f3loga Cl\u00ednica","id_on_source":"drarequena","tweeter_id":"580314999","geo":{"lt":36.77262,"ln":-4.10045,"country":"ES"},"followers":844},"tweet_id":"396216192668798976"},{"url":"https:\/\/twitter.com\/Interasma\/status\/396237108287115264","license":"public","citation_ids":[1341110],"posted_on":"2013-11-01T11:27:43+00:00","author":{"name":"Interasma","url":"http:\/\/www.interasma.org","image":"https:\/\/pbs.twimg.com\/profile_images\/481070665450016770\/o6EbOA8x_normal.jpeg","description":"Interasma is an international health organization focused on all aspects of asthma which bridges the gap between academia and the world of clinical practice.","id_on_source":"Interasma","tweeter_id":"147594153","geo":{"lt":null,"ln":null},"followers":1584},"tweet_id":"396237108287115264"}],"googleplus":[{"title":"Add-on omalizumab in children with severe allergic asthma: a one year real life survey.","url":"https:\/\/plus.google.com\/115278038144902833946\/posts\/RyQTTnkx2UX","citation_ids":[1341110],"posted_on":"2013-04-30T11:33:43+00:00","summary":"Add-on omalizumab in children with severe allergic asthma: a one year real life survey. Add-on omalizumab in children with severe allergic asthma: a one year real life survey. Add-on omalizumab in children with severe allergic asthma: a one year real life","author":{"name":"Juan Carlos Ivancevich","url":"https:\/\/plus.google.com\/+JuanCarlosIvancevichMD","image":"https:\/\/lh6.googleusercontent.com\/-tlJ5gfZslpE\/AAAAAAAAAAI\/AAAAAAAAeZ4\/t6mCbsfjhOg\/photo.jpg?sz=50","id_on_source":"115278038144902833946"}},{"title":"Add-on omalizumab in children with severe allergic asthma: a one year real life survey.","url":"https:\/\/plus.google.com\/115278038144902833946\/posts\/QeR2ZgeqQen","citation_ids":[1341110],"posted_on":"2013-03-25T12:38:05+00:00","summary":"Add-on omalizumab in children with severe allergic asthma: a one year real life survey. Add-on omalizumab in children with severe allergic asthma: a one year real life survey. Add-on omalizumab in children with severe allergic asthma: a one year real life","author":{"name":"Juan Carlos Ivancevich","url":"https:\/\/plus.google.com\/+JuanCarlosIvancevichMD","image":"https:\/\/lh6.googleusercontent.com\/-tlJ5gfZslpE\/AAAAAAAAAAI\/AAAAAAAAeZ4\/t6mCbsfjhOg\/photo.jpg?sz=50","id_on_source":"115278038144902833946"}}]}}